Stewart Jeffrey Ryan reported option exercise involving 16,070 derivative units of AbbVie Inc. at $0.00 for $0 on Nov 9, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
EVP, CHIEF COMMERCIAL OFFICER
EVP, CHIEF COMMERCIAL OFFICER
Filed Nov 12, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
16,070Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
0Direct
Trade date
Nov 9, 2026Option exercise
Filed
Nov 12, 2026, 5:00 PM ET3-day reporting delay
Accession
0001761675-26-000007Code M · Transaction 399342
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Nov 12, 2026Gift3,450$0.00$0Trade 399341
Nov 9, 2026Option exercise16,070$114.36$1,837,765.20Trade 399338
Nov 9, 2026Option exercise24,549$93.50$2,295,331.50Trade 399339
Nov 9, 2026Option exercise24,549$0.00$0Trade 399343
Nov 9, 2026Sell40,619$293.60−$11,925,738.40Trade 399340
6 transaction rows in this filing. Joint filers share the same rows.

ABBV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABBV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Nov 19, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago −3.5%1w ago 0%1d ago 0%
Returns since7d30d90d180d1y

Footnotes in full

F1: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $293.54 to $293.82, inclusive. The reporting person undertakes to provide AbbVie Inc., any security holder of AbbVie Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote F2: The reporting person disclaims beneficial ownership of all securities held by his spouse. F3: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 5,357 on February 15, 2019, 5,356 on February 15, 2020, and 5,357 on February 15, 2021. F4: Employee stock option granted pursuant to the AbbVie Amended and Restated 2013 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 16,367 on February 20, 2021, 16,366 on February 20, 2022, and 16,366 on February 20, 2023.